At TNI BioTech, Inc., our goal is to benefit patients with chronic and often life-threatening diseases through the activation and rebalancing of the body's immune system using our patented immunotherapy.
Our products, technologies, and patents are designed to harness the power of the immune system to improve the treatment of cancer and infections, such as HIV/AIDS and autoimmune diseases. We are currently developing active and adoptive forms of immunotherapies.
Our most advanced clinical programs involve immunotherapy with methionine-enkephalin (MENK) or low dose naltrexone, which both work by triggering opioid receptors on immune cells and lead to an activation and expansion of various cells in the immune system.
* This video was published in January 2013. The information contained in this video speaks only as of January 2013, and TNI BioTech, Inc. has, and accepts, no responsibility or duty to update any such information and reserves the right to add to, remove or amend any information contained in this video. This video may contain projections or other forward-looking statements regarding a variety of items. Such forward-looking statements are based upon expectations as of the date of this video and involve risks and uncertainties. Actual results may differ materially from those stated in any forward-looking statement based on a number of important factors and risks, which are more specifically identified in our most recent Securities and Exchange Commission filings. Although we may indicate and believe that the assumptions underlying the forward-looking statements are reasonable, any of the assumptions could prove inaccurate or incorrect and, therefore, there can be no assurance that the results contemplated in the forward-looking statements will be realized.
Methionine-enkephalin (Met-Enk) and leucine-enkephalin (Leu-Enk) belong to family of opioid peptides.
In vivo studies on immunomodulating activity of enkephalins performed in the rat revealed the following: (a) both neuropentapeptides showed a dual, dose-dependent effect, i.e., high doses suppressed while low doses potentiated immune responses; (b) Met-Enk is more potent immunomodulator than Leu-Enk; (c) high doses of Met-Enk suppressed immune inflammatory reactions, such as systemic anaphylactic shock, Arthus and delayed hypersensitivity skin reactions to protein antigen, allograft rejection, adjuvant arthritis, and experimental allergic encephalomyelitis. Met-Enk is more efficient when applied intracerebroventricularly. A preliminary clinical trial showed that intrathecally given Met-Enk exerted a beneficial effect on 13 patients with chronic severe progressive multiple sclerosis.